翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | H 股 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | | | A. 已發行股份或庫存股份變動 | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | | 事件 | 已發行股份 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% relative to the market benchmark index within the next six months [10]. Core Views - The company has demonstrated stable revenue growth, with a significant increase in the medical aesthetics segment, which accounted for a growing share of total revenue. In the first half of 2024, the company achieved revenue of 1.404 billion yuan, a year-on-year increase of 6.97%, and a net profit attributable to shareholders of 235 million yuan, up 14.64% year-on-year [1]. - The hyaluronic acid product line has gained market recognition, with revenue in the first half of 2024 reaching 417 million yuan, reflecting a substantial year-on-year growth of 51.3%. The company is expanding its product portfolio and enhancing brand loyalty through various marketing strategies [1]. - The company is accelerating the localization process in its ophthalmology product line, despite facing challenges in revenue from certain segments due to policy impacts and market competition. The report highlights the competitive strength of specific products, such as "myOK" and "童享," which have shown significant growth in prescriptions [1]. Financial Summary - The company is projected to achieve revenues of 2.903 billion yuan, 3.392 billion yuan, and 4.042 billion yuan for the years 2024, 2025, and 2026, respectively. The net profit attributable to shareholders is expected to be 508 million yuan, 638 million yuan, and 779 million yuan for the same years [2][3]. - The earnings per share (EPS) is forecasted to be 2.16 yuan, 2.71 yuan, and 3.31 yuan for 2024, 2025, and 2026, respectively, with corresponding price-to-earnings (P/E) ratios of 28.6, 22.8, and 18.7 [3][4]. - The company’s financial health is reflected in its asset-liability ratio of 16.38% and a circulating A-share market value of approximately 11.994 billion yuan [4].

证券代码：688366 证券简称：昊海生科 公告编号：2024-045 上海昊海生物科技股份有限公司 关于变更注册资本并修订公司章程的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海昊海生物科技股份有限公司（以下简称"公司"）于 2024 年 8 月 19 日 召开第五届董事会第二十六次会议，审议通过了《关于变更公司注册资本并修订 公司章程的议案》等议案，现将相关事项公告如下： 一、变更注册资本 上海昊海生物科技股份有限公司董事会 公司分别于 2024 年 3 月 8 日、2024 年 5 月 29 日召开第五届董事会第二十 次会议，2023 年度股东周年大会、2024 年第一次 A 股类别股东大会及 2024 年 第一次 H 股类别股东大会，审议通过了《关于公司 2023 年度利润分配及资本公 积金转增股本预案的议案》，同意公司以实施权益分派登记日登记的总股本扣除 公司回购专用证券账户中的股份为基数，向全体股东每 10 股派发现金红利 10.00 元，同时，以资本公积金向全体股东每 10 股转增 4 股。公司已 ...

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [1] Core Views - The company's H1 2024 net profit increased by 14.64%, meeting expectations, with revenue of 1.404 billion yuan (+6.97%) and net profit of 235 million yuan (+14.64%) [1] - The medical beauty business continues to show high growth, with the fourth-generation hyaluronic acid product "Haimi Yuebai" approved, expected to drive sales [1] - The ophthalmology segment experienced a revenue decline due to centralized procurement and price reductions, while the orthopedics segment showed recovery [1] Summary by Sections Financial Performance - For H1 2024, revenue was 1.404 billion yuan, with a net profit of 235 million yuan, and a net profit margin of 16.8%, up 1.1 percentage points year-on-year [1] - The gross margin for H1 2024 was 70.51%, slightly down by 0.5 percentage points, while the net profit margin improved [1][3] Business Segments - Medical beauty revenue reached 634 million yuan (+25.72%), with hyaluronic acid revenue at 417 million yuan (+51.3%) [1] - The ophthalmology segment's revenue was 452 million yuan (-6.02%), with cataract business revenue at 232 million yuan (-10.7%) [1] - Orthopedic revenue was 233 million yuan (+0.42%), with a consistent market position in joint injection products [1] Future Outlook - Revenue projections for 2024-2026 are adjusted to 2.985 billion yuan, 3.392 billion yuan, and 3.816 billion yuan, respectively, with net profits of 495 million yuan, 599 million yuan, and 721 million yuan [1][3] - The company is expected to benefit from the dual drivers of medical beauty and pharmaceuticals, with a projected PE of 28X, 23X, and 19X for the respective years [1]

Investment Rating - The report maintains a "Buy" rating for the company [4]. Core Insights - The company achieved revenue, net profit attributable to shareholders, and net profit excluding non-recurring items of 1.404 billion, 235 million, and 230 million RMB respectively in the first half of 2024, representing year-on-year growth of 6.97%, 14.64%, and 22.66% [2]. - The innovative hyaluronic acid product "Haimi" continues to drive significant growth, with the hyaluronic acid segment generating 417 million RMB in revenue, marking a 51% year-on-year increase [3]. - The company is expanding its product line with the upcoming launch of the fourth-generation organic cross-linked hyaluronic acid "Haimi Moon White," which is expected to enhance marketing efforts and profitability [3]. - The ophthalmology segment is poised for growth with the anticipated approval of innovative hydrophobic injection artificial lenses, despite a decline in revenue due to price reductions from centralized procurement [3]. Summary by Sections Performance Overview - In the first half of 2024, the company reported revenue of 1.404 billion RMB, net profit of 235 million RMB, and net profit excluding non-recurring items of 230 million RMB, with respective year-on-year growth rates of 6.97%, 14.64%, and 22.66% [2]. Medical Aesthetics - The medical aesthetics segment generated 417 million RMB in revenue, achieving a 51% year-on-year growth, driven by the innovative product "Haimi" [3]. - The third-generation hyaluronic acid product features high cohesiveness and natural results, contributing significantly to revenue growth [3]. Ophthalmology - The ophthalmology segment reported revenue of 452 million RMB, a decline of 6.02% year-on-year, primarily due to price reductions from centralized procurement [3]. - The company is investing in R&D, with expenses of 125 million RMB in the first half of 2024, a 23.68% increase year-on-year, indicating a commitment to innovation [3]. Financial Projections - The revenue forecast for 2024 and 2025 has been adjusted downwards to 3.2 billion and 3.85 billion RMB, respectively, with net profit projections also lowered to 515 million and 635 million RMB [4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 1.404 billion yuan in H1 2024, representing a year-on-year increase of 6.97%, and a net profit attributable to shareholders of 235 million yuan, up 14.64% [2] - The medical aesthetics segment grew over 25%, with hyaluronic acid products increasing by over 50% [2] - The ophthalmology segment faced revenue pressure, with a decline of 6.02% in H1 2024, although new products like the OK lens showed positive growth [2][3] - The orthopedics segment remained stable, while the surgical segment experienced a slight decline [3] - The company is expected to achieve net profits of 5.11 billion yuan, 6.32 billion yuan, and 7.61 billion yuan for 2024, 2025, and 2026 respectively, with corresponding P/E ratios of 27, 22, and 18 [3] Summary by Sections Financial Performance - Total revenue for 2022 was 2.13 billion yuan, increasing to 2.654 billion yuan in 2023, with projections of 2.902 billion yuan in 2024 [1] - Net profit attributable to shareholders was 180.47 million yuan in 2022, rising to 416.12 million yuan in 2023, and expected to reach 511.20 million yuan in 2024 [1] - The latest diluted EPS is projected to be 2.17 yuan for 2024, with a P/E ratio of 27.47 [1] Segment Performance - The medical aesthetics segment generated 634 million yuan in H1 2024, with hyaluronic acid products contributing 417 million yuan [2] - The ophthalmology segment generated 452 million yuan in H1 2024, with a notable decline in artificial lens revenue [3] - The orthopedics segment achieved 233 million yuan in revenue, while the surgical segment saw a slight decrease [3] Future Outlook - The company is expected to maintain strong growth in its medical aesthetics products, while the ophthalmology segment may recover post-collection [3] - The approval of the fourth-generation hyaluronic acid product is anticipated to sustain high growth rates in the premium product line [2]

EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 上海昊海生物科技股份有限公司 | | 股份代號 | 06826 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 截至2024年6月30日止六個月期間之中期業績公告 | | | 公告日期 | 2024年8月16日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年6月30日 | | 宣派股息 | 每 股 0.4 RMB | | 股東批准日期 | 有待公佈 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | HKD， 金額有待公佈 | | 匯率 | 有待公佈 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 截至2024年6月30日止六個月期間之中期業績公告 截至2024年6月30日止六個月期間之中期業績摘要 • 報告期內，本集團共錄得營業收入約人民幣1,397.11百萬元（2023年同期：約 人民幣1,305.71百萬元），較2023年同期增加約人民幣91.40百萬元，增幅約 為7.00%。 • 報告期內，本集團研發開支約人民幣125.40百萬元，較2023年同期增加約人 民幣24.01百萬元，增幅約為23.68%，本集團研發開支佔收入比重為8.98% （2023年同期：7.77%）。 • 報告期內，本公司普通股權益持有人應佔利潤約為人民幣235.28百萬元（2023 年同期：約人民幣205.24百萬元），較20 ...

上海昊海生物科技股份有限公司 募集资金管理制度 上海昊海生物科技股份有限公司 第三条 公司董事会应当负责建立健全公司募集资金管理制度，并确保该 制度的有效实施。募集资金管理制度应当对募集资金专户存储、使用、变更、 监督和责任追究等内容进行明确规定。 公司董事、监事和高级管理人员应当勤勉尽责，督促公司规范使用募集资金， 自觉维护公司募集资金安全，不得参与、协助或纵容公司擅自或变相改变募集资 金用途。 公司控股股东、实际控制人不得直接或者间接占用或者挪用公司募集资金， 不得利用公司募集资金及募集资金投资项目（以下简称"募投项目"）获取不正 当利益。 募投项目通过公司的子公司或公司控制的其他企业实施的，公司应当确保该 1 上海昊海生物科技股份有限公司 募集资金管理制度 募集资金管理制度 第一章 总 则 第一条 为规范上海昊海生物科技股份有限公司（以下简称"公司"）募集 资金的使用与管理，提高募集资金的使用效率，防范资金使用风险，确保资金使 用安全，保护投资者的利益，根据《中华人民共和国公司法》、《中华人民共和 国证券法》、《上市公司证券发行注册管理办法》、《上市公司监管指引第2号 ——上市公司募集资金管理和使用的监 ...